Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527163 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL5886445 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL15215108 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL1486173 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL5343118 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL1486171 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL8048104 | 1.00 | CTSK (0.46) | CTSKCTSSCA12CA14CA1 | |
| Acetonitrile SCHEMBL28263421 | 0.92 | CTSK (0.51) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL28411968 | 0.91 | CTSK (0.47) | CTSKCTSSCA12CA14CA1 | |
| SCHEMBL20825614 | 0.91 | CTSK (0.47) | CTSKCTSSCA12CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-09-12 | — | — | US | disclosed |
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-113166143-A | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods | 3M创新有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-1304380-C | Benzo[a]henazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LTD (GB) | 2007-03-14 | — | — | CN | disclosed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| CN-1433406-A | Benzo [ a ] phenazine-11-amide derivatives and their use as combined topoisomerase I and II inhibitors | XENOVA LTD (GB) | 2003-07-30 | — | — | CN | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IRF3, IFNAR1, IFNG | CTSK 3214/4885CTSS 3046/4885CA12 1062/4885 |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | IFNG, IFNAR1, IRF3 | CTSK 3629/4885CTSS 3196/4885CA12 4324/4885 |
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | CTSK 3439/4885CTSS 3151/4885CA12 638/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | CTSK 3950/4885CTSS 3181/4885CA12 229/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | CTSK 3716/4885CTSS 3500/4885CA12 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.